Your browser doesn't support javascript.
loading
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe.
Forster, Sophie; Wiseman, Scott; Snyder, Daniel E.
Affiliation
  • Forster S; Elanco Animal Health, Bartley Way, Bartley Wood Business Park, Hook, Hants, RG27 9XA, UK.
  • Wiseman S; Elanco Animal Health, Bartley Way, Bartley Wood Business Park, Hook, Hants, RG27 9XA, UK.
  • Snyder DE; Daniel E. Snyder, DVM PhD. Consulting, LLC, Indianapolis, IN, 46229, USA. Daniel.Snyder@network.elancoah.com.
Parasit Vectors ; 14(1): 299, 2021 Jun 04.
Article in En | MEDLINE | ID: mdl-34088338
BACKGROUND: A pivotal randomised, blinded, positive-controlled, multicentre, European field study was conducted to evaluate the effectiveness and safety of a novel combination tablet of lotilaner and milbemycin oxime (Credelio® Plus) administered orally to client-owned dogs naturally infested with fleas and/or ticks. METHODS: In this field study, households with flea- or tick-infested dog(s) were enrolled on Day 0 into the study to provide data for either the tick or flea infestation cohorts. Households were randomised in a 2:1 ratio to receive either the combination investigational product (IP, Credelio Plus® tablets) or the control product (CP: Nexgard Spectra® tablets). Dogs were administered IP (flea cohort n = 135; tick cohort: n = 147) or CP (flea cohort: n = 67; tick cohort: n = 74) once every 4 weeks for a total of three times at a dose rate of 20.0-41.5 mg/kg bodyweight lotilaner and 0.75-1.53 mg/kg bodyweight milbemycin oxime (IP) or as recommended (CP). Percentage reduction was calculated by comparing individual dog flea and tick counts at each assessed post-treatment time point to their respective baseline (pre-treatment) infestation. Resolution of the clinical signs of flea allergy dermatitis (FAD) was assessed in flea-allergic dogs on the days that flea counts were performed. RESULTS: Flea effectiveness of Credelio Plus® after 3 consecutive monthly treatments was 100% against Ctenocephalides felis, C. canis and Pulex irritans. Tick effectiveness of Credelio Plus® over the same time frame was 99.3% for Ixodes ricinus and 100% against Rhipicephalus sanguineus (s.l.). Flea effectiveness of the CP after three consecutive monthly treatments was 100% against C. felis, C. canis and P. irritans. Tick effectiveness of the CP over the same time frame was 99.8% for I. ricinus and 100% against R. sanguineus. Credelio Plus® was well tolerated based on the safety assessments in all treated dogs in this field study. Within both treatment groups there was a reduction in total FAD scores from baseline. CONCLUSIONS: This pivotal European field study demonstrated the excellent effectiveness and safety of a combination of lotilaner and milbemycin oxime (Credelio Plus®) administered orally to dogs naturally infested with fleas and/or ticks.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Thiophenes / Tick Infestations / Macrolides / Dog Diseases / Flea Infestations Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Animals Country/Region as subject: Europa Language: En Journal: Parasit Vectors Year: 2021 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Thiophenes / Tick Infestations / Macrolides / Dog Diseases / Flea Infestations Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Animals Country/Region as subject: Europa Language: En Journal: Parasit Vectors Year: 2021 Document type: Article Country of publication: